{"id":14148,"date":"2014-05-28T11:01:35","date_gmt":"2014-05-28T09:01:35","guid":{"rendered":"https:\/\/www.izb-online.de\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/"},"modified":"2020-09-28T11:01:58","modified_gmt":"2020-09-28T09:01:58","slug":"4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco","status":"publish","type":"gco_media","link":"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/","title":{"rendered":"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"featured_media":0,"template":"","meta":{"_links_to":"","_links_to_target":""},"media-categories":[9710],"class_list":["post-14148","gco_media","type-gco_media","status-publish","hentry","media-categories-2014-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"article:modified_time\" content=\"2020-09-28T09:01:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\\\/\",\"name\":\"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\"},\"datePublished\":\"2014-05-28T09:01:35+00:00\",\"dateModified\":\"2020-09-28T09:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRESS RELEASE\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/media-library\\\/press-release\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"2014\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/media-library\\\/press-release\\\/2014-en\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"name\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"description\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\",\"name\":\"F\u00f6rdergesellschaft IZB mbH\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"F\u00f6rdergesellschaft IZB mbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/","og_locale":"en_US","og_type":"article","og_title":"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO","og_url":"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/","og_site_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","article_modified_time":"2020-09-28T09:01:58+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/","url":"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/","name":"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/#website"},"datePublished":"2014-05-28T09:01:35+00:00","dateModified":"2020-09-28T09:01:58+00:00","breadcrumb":{"@id":"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/4sc-announces-positive-top-line-data-from-clinical-phase-i-trial-with-epigenetic-cancer-drug-4sc-202-in-patients-with-haematological-tumours-at-asco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.izb-online.de\/en\/"},{"@type":"ListItem","position":2,"name":"PRESS RELEASE","item":"https:\/\/www.izb-online.de\/en\/media-library\/press-release\/"},{"@type":"ListItem","position":3,"name":"2014","item":"https:\/\/www.izb-online.de\/en\/media-library\/press-release\/2014-en\/"},{"@type":"ListItem","position":4,"name":"4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO"}]},{"@type":"WebSite","@id":"https:\/\/www.izb-online.de\/en\/#website","url":"https:\/\/www.izb-online.de\/en\/","name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"Innovations- und Gr\u00fcnderzentrum Biotechnologie","publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.izb-online.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.izb-online.de\/en\/#organization","name":"F\u00f6rdergesellschaft IZB mbH","url":"https:\/\/www.izb-online.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","width":1,"height":1,"caption":"F\u00f6rdergesellschaft IZB mbH"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_media\/14148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_media"}],"about":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/types\/gco_media"}],"wp:attachment":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media?parent=14148"}],"wp:term":[{"taxonomy":"media-categories","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media-categories?post=14148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}